InQu, a hyaluronic acid-based bone graft extender and substitute, offers a number of surgical advantages. A combination of hyaluronic acid and PLGA, InQu provides a unique microenvironment that is conducive to bone formation.

Unlike ceramic bone graft substitutes, which are slowly replaced during bone healing, InQu’s rate of resorption is consistent with the rate of bone remodeling at the site of implantation, thus providing the surgeon with predictable results. This unique biomaterial was designed to optimize handling during surgery and to allow unobscured radiographic monitoring of new bone formation. InQu is currently available for use as a bone graft extender and substitute.

Click to Learn More

NuQu, currently in early-stage development, is a cell-based therapy aimed at resolving the cause of back pain associated with degenerative disc disease. NuQu is composed of a protein-based carrier and culture-expanded juvenile articular cartilage cells which have been proved to have far greater regenerative potential than their adult counterparts.

Ongoing studies with NuQu show great promise in retaining the injectable product in the spinal disc and restoring nucleus structure and disc height. By addressing the underlying cause of degenerative disc disease through biological solutions, NuQu’s technology provides hope in restoring tissue function, and may become a life-changing, long-term solution to back pain.

Click to Learn More

DeNovo ET is a scaffold-free living cartilage implant designed for the repair and regeneration of knee cartilage. The DeNovo ET hyaline cartilage implant displays biochemical properties similar to those of cartilage found in young, healthy joints. Because cells used to produce DeNovo ET come from juvenile tissue, DeNovo ET is expected to heal and regenerate damaged joint cartilage more effectively than technologies based on adult cells. This product is currently in clinical trials.

DeNovo^® is a registered trademark of Zimmer Holdings, Inc.

Click to Learn More